142 related articles for article (PubMed ID: 20213647)
41. Overexpression of PTEN increases sensitivity to SN-38, an active metabolite of the topoisomerase I inhibitor irinotecan, in ovarian cancer cells.
Saga Y; Mizukami H; Suzuki M; Kohno T; Urabe M; Ozawa K; Sato I
Clin Cancer Res; 2002 May; 8(5):1248-52. PubMed ID: 12006545
[TBL] [Abstract][Full Text] [Related]
42. [Inhibitors of DNA topoisomerases].
Andoh T
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1526-35. PubMed ID: 9309151
[TBL] [Abstract][Full Text] [Related]
43. Gossypol interferes with both type I and type II topoisomerase activities without generating strand breaks.
Senarisoy M; Canturk P; Zencir S; Baran Y; Topcu Z
Cell Biochem Biophys; 2013 May; 66(1):199-204. PubMed ID: 23161103
[TBL] [Abstract][Full Text] [Related]
44. DNA topoisomerase I poisons.
Takimoto CH; Kieffer LV; Kieffer ME; Arbuck SG; Wright J
Cancer Chemother Biol Response Modif; 1999; 18():81-124. PubMed ID: 10800479
[No Abstract] [Full Text] [Related]
45. Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan.
Subramanian D; Muller MT
Oncol Res; 1995; 7(9):461-9. PubMed ID: 8835290
[TBL] [Abstract][Full Text] [Related]
46. In vivo topoisomerase I inhibition attenuates the expression of hypoxia-inducible factor 1α target genes and decreases tumor angiogenesis.
Guérin E; Raffelsberger W; Pencreach E; Maier A; Neuville A; Schneider A; Bachellier P; Rohr S; Petitprez A; Poch O; Moras D; Oudet P; Larsen AK; Gaub MP; Guenot D
Mol Med; 2012 Feb; 18(1):83-94. PubMed ID: 22033674
[TBL] [Abstract][Full Text] [Related]
47. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.
Jacob S; Aguado M; Fallik D; Praz F
Cancer Res; 2001 Sep; 61(17):6555-62. PubMed ID: 11522654
[TBL] [Abstract][Full Text] [Related]
48. Camptothecin analogues with enhanced antitumor activity at acidic pH.
Adams DJ; Dewhirst MW; Flowers JL; Gamcsik MP; Colvin OM; Manikumar G; Wani MC; Wall ME
Cancer Chemother Pharmacol; 2000; 46(4):263-71. PubMed ID: 11052623
[TBL] [Abstract][Full Text] [Related]
49. CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues.
Guichard S; Terret C; Hennebelle I; Lochon I; Chevreau P; Frétigny E; Selves J; Chatelut E; Bugat R; Canal P
Br J Cancer; 1999 May; 80(3-4):364-70. PubMed ID: 10408839
[TBL] [Abstract][Full Text] [Related]
50. An overview of topoisomerase I-targeting agents.
Arbuck SG; Takimoto CH
Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
[TBL] [Abstract][Full Text] [Related]
51. Betulinic acid, a potent inhibitor of eukaryotic topoisomerase I: identification of the inhibitory step, the major functional group responsible and development of more potent derivatives.
Chowdhury AR; Mandal S; Mittra B; Sharma S; Mukhopadhyay S; Majumder HK
Med Sci Monit; 2002 Jul; 8(7):BR254-65. PubMed ID: 12118187
[TBL] [Abstract][Full Text] [Related]
52. Prevention of intestinal toxic effects and intensification of irinotecan's therapeutic efficacy against murine colon cancer liver metastases by oral administration of the lipopeptide JBT 3002.
Shinohara H; Killion JJ; Kuniyasu H; Kumar R; Fidler IJ
Clin Cancer Res; 1998 Sep; 4(9):2053-63. PubMed ID: 9748119
[TBL] [Abstract][Full Text] [Related]
53. Camptothecins inhibit the utilization of hydrogen peroxide in the ligation step of topoisomerase I catalysis.
Lisby M; Krogh BO; Boege F; Westergaard O; Knudsen BR
Biochemistry; 1998 Jul; 37(30):10815-27. PubMed ID: 9692972
[TBL] [Abstract][Full Text] [Related]
54. Ubiquitin-family modifications of topoisomerase I in camptothecin-treated human breast cancer cells.
Kanagasabai R; Liu S; Salama S; Yamasaki EF; Zhang L; Greenchurch KB; Snapka RM
Biochemistry; 2009 Apr; 48(14):3176-85. PubMed ID: 19236054
[TBL] [Abstract][Full Text] [Related]
55. Action models for the antitumor drug camptothecin: formation of alkali-labile complex with DNA and inhibition of human DNA topoisomerase I.
Streltsov SA
J Biomol Struct Dyn; 2002 Dec; 20(3):447-54. PubMed ID: 12437383
[TBL] [Abstract][Full Text] [Related]
56. DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition.
Pommier Y
Chem Rev; 2009 Jul; 109(7):2894-902. PubMed ID: 19476377
[No Abstract] [Full Text] [Related]
57. A theoretical study of some new analogues of the anti-cancer drug camptothecin.
Jena NR; Mishra PC
J Mol Model; 2007 Jan; 13(1):267-74. PubMed ID: 17024403
[TBL] [Abstract][Full Text] [Related]
58. A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex.
Marchand C; Antony S; Kohn KW; Cushman M; Ioanoviciu A; Staker BL; Burgin AB; Stewart L; Pommier Y
Mol Cancer Ther; 2006 Feb; 5(2):287-95. PubMed ID: 16505102
[TBL] [Abstract][Full Text] [Related]
59. Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs.
Lansiaux A; Léonce S; Kraus-Berthier L; Bal-Mahieu C; Mazinghien R; Didier S; David-Cordonnier MH; Hautefaye P; Lavielle G; Bailly C; Hickman JA; Pierré A
Mol Pharmacol; 2007 Aug; 72(2):311-9. PubMed ID: 17494837
[TBL] [Abstract][Full Text] [Related]
60. The dual topoisomerase inhibitor, BN 80927, is highly potent against cell proliferation and tumor growth.
Huchet M; Demarquay D; Coulomb H; Kasprzyk P; Carlson M; Lauer J; Lavergne O; Bigg D
Ann N Y Acad Sci; 2000; 922():303-5. PubMed ID: 11193907
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
